Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$1.02 - $3.23 $1,161 - $3,678
-1,139 Reduced 3.59%
30,594 $38,000
Q4 2023

Feb 12, 2024

BUY
$1.72 - $3.18 $5,930 - $10,964
3,448 Added 12.19%
31,733 $86,000
Q3 2023

Nov 13, 2023

SELL
$2.13 - $5.55 $1,603 - $4,179
-753 Reduced 2.59%
28,285 $64,000
Q2 2023

Aug 11, 2023

BUY
$3.6 - $5.25 $104,536 - $152,449
29,038 New
29,038 $126,000
Q4 2022

Feb 13, 2023

SELL
$5.66 - $8.42 $742,903 - $1.11 Million
-131,255 Reduced 18.56%
575,931 $4.85 Million
Q3 2022

Nov 14, 2022

BUY
$3.02 - $6.12 $1.88 Million - $3.8 Million
620,953 Added 720.09%
707,186 $4.33 Million
Q2 2022

Aug 15, 2022

BUY
$2.6 - $6.14 $4,440 - $10,487
1,708 Added 2.02%
86,233 $270,000
Q1 2022

May 16, 2022

BUY
$5.08 - $9.81 $336,743 - $650,285
66,288 Added 363.48%
84,525 $482,000
Q4 2021

Feb 14, 2022

SELL
$8.55 - $111.89 $468,274 - $6.13 Million
-54,769 Reduced 75.02%
18,237 $179,000
Q3 2021

Nov 15, 2021

SELL
$76.53 - $110.43 $1.25 Million - $1.8 Million
-16,335 Reduced 18.28%
73,006 $7.73 Million
Q2 2021

Aug 17, 2021

BUY
$85.37 - $114.1 $849,516 - $1.14 Million
9,951 Added 12.53%
89,341 $7.63 Million
Q1 2021

May 17, 2021

BUY
$109.73 - $153.66 $2.89 Million - $4.05 Million
26,369 Added 49.73%
79,390 $9.11 Million
Q4 2020

Feb 16, 2021

BUY
$79.58 - $152.45 $4.22 Million - $8.08 Million
53,021 New
53,021 $7.42 Million
Q4 2019

Feb 14, 2020

SELL
$66.49 - $137.73 $3.58 Million - $7.42 Million
-53,853 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$31.0 - $89.73 $1.67 Million - $4.83 Million
53,853 New
53,853 $4.23 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $89.8M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.